Tag: Apnimed
Apnimed backs OSA pill with two new peer-reviewed articles
May 19, 2026HME News Staff
CAMBRIDGE, Mass. – Apnimed has published two peer-reviewed articles on AD109 (aroxybutynin 2.5 mg/atomoxetine 75 mg), an investigational, once-daily oral pill taken at bedtime designed to improve oxygenation and target the neuromuscular root cause of obstructive sleep apnea (OSA). The Phase 3 SynAIRgy trial results are published in the American Journal of Respiratory and Critical Care Medicine (AJRCCM), alongside a companion mechanistic review article in the American Journal of Respiratory...
Apnimed secures $150M in debt financing ahead of planned launch of pill to treat OSA
April 7, 2026HME News Staff
CAMBRIDGE, Mass. – Apnimed, a pharmaceutical company developing oral therapies for obstructive sleep apnea (OSA), has entered into a senior secured credit facility for up to $150 million with funds managed by HealthCare Royalty Partners (HCRx). The company plans to use the capital to support commercial readiness activities and the planned U.S. launch of its lead product candidate, AD109, if approved by the U.S. Food and Drug Administration (FDA). "HCR is a highly respected health care...
In brief: Inogen’s activist investor, industry’s fraud recs, Apnimed’s financing
April 3, 2026HME News Staff
BEVERLY, Mass. – Inogen has named Vafa Jamali to its board as an independent director and, in connection with that appointment, has entered into a cooperation agreement with Kent Lake Partners.
As CEO of ZimVie, Jamali led the company’s Nasdaq listing following the spin-out from Zimmer Biomet and helped each of the businesses (Spine and Dental) through significant portfolio optimization actions to support a turnaround to higher growth and profitability. Prior to ZimVie, he spent nearly...
In brief: Indie provider’s role, Nonin’s milestone, Cardinal’s new chair
March 27, 2026HME News Staff
YARMOUTH, Maine – MiraVista is hosting “The Once and Future Role of the Independent DME Supplier” on March 31, 2026, at 2:00 PM ET. The free webinar will bring together a cross-disciplinary panel of experts to discuss a regulatory environment that the company says increasingly and incorrectly brands small and independent DME suppliers as core causes of fraud, waste and abuse in the health care system. The company says the discussion is aimed at the broader narrative that...
Apnimed receives $100M for joint venture
March 25, 2026HME News Staff
CAMBRIDGE, Mass. - Apnimed, a pharmaceutical company developing an oral drug product candidate, AD109, that is designed to address a root cause of obstructive sleep apnea (OSA), today announced that Shionogi & Co. Ltd (Shionogi) has entered into a definitive agreement to acquire Apnimed's 50% ownership of Shionogi-Apnimed Sleep Science, LLC (SASS). SASS is a joint venture initially established in 2023, and upon the closing of this transaction, SASS will be wholly-owned by...
Apnimed sees Phase 2 positive results for sulthiame to treat OSA
November 4, 2025HME News Staff
CAMBRIDGE, Mass. - Apnimed has announced The Lancet has published positive results from the Phase 2 FLOW study evaluating sulthiame, a differentiated, once-daily oral carbonic anhydrase inhibitor, in the treatment of obstructive sleep apnea (OSA).
The study demonstrated that sulthiame significantly improved important OSA metrics in adults with moderate to severe OSA, the company says.
"The positive data from the FLOW trial confirm previous...
In brief: Push for timeline, win for knee orthoses, results for Apnimed
July 30, 2025HME News Staff
WASHINGTON – AAHomecare, the COPD Foundation, the Council for Quality Respiratory Care and VGM Government Relations have formally requested that CMS establish a clear implementation timeline for the new national coverage determination for non-invasive positive pressure ventilation.
In a letter sent July 23, the groups asked CMS to delay implementation until at least one year after the NCD’s publication date of June 9.
“Adopting a clear implementation glidepath...
Apnimed announces positive results for sleep apnea pill, plans FDA filing
July 28, 2025HME News Staff
CAMBRIDGE, Mass. – Apnimed, a pharmaceutical company developing oral therapies for obstructive sleep apnea (OSA) and related conditions, announced positive topline results from its second pivotal Phase 3 trial of AD109 (aroxybutynin 2.5mg/atomoxetine 75mg). The 12-month LunAIRo study assessed the efficacy and safety of AD109 in adults with mild to severe OSA across various weight classes. The primary endpoint, measured at 26 weeks, was met with a 46.8% mean reduction in AHI compared to 6.8%...
In brief: KabaFusion expands footprint, CGM reduces hospitalizations, Apnimed shares positive results
May 21, 2025HME News Staff
LEXINGTON, Mass. – KabaFusion has closed on the acquisition of six locations from Coram that will serve as pharmacies and ambulatory infusion suites.
The transaction will expand KabaFusion’s ability to serve a growing number of patients nationwide and strengthen its commitment to deliver high-quality patient care across a broad range of therapies, the company says.
“Our expansion will enable KabaFusion to serve a greater number of patients with superior...
Apnimed shares positive results for sleep apnea pill
May 19, 2025HME News Staff
CAMBRIDGE, Mass. - Apnimed has announced positive topline results from its pivotal Phase 3 SynAIRgy clinical trial evaluating the efficacy and safety of AD109 in adults living with mid, moderate and severe OSA and across all weight classes. The SynAIRgy trial met its primary endpoint: mean change from baseline in the apnea-hypopnea index (AHI) at 26 weeks compared to placebo (p=0.001). “Today is a landmark moment for Apnimed and for millions living with OSA who have long struggled with limited...